Rimadyl Palatable Tablets 50 mg

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

Aktif bileşen:

Carprofen

Mevcut itibaren:

Zoetis Belgium S.A.

ATC kodu:

QM01AE91

INN (International Adı):

Carprofen

Doz:

50 mg/tablet

Farmasötik formu:

Tablet

Reçete türü:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapötik grubu:

Dogs

Terapötik alanı:

carprofen

Terapötik endikasyonlar:

N.S.A.I.D.

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2015-03-06

Ürün özellikleri

Health Products Regulatory Authority
29 April 2020
CRN009NWW
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimadyl Palatable Tablets 50 mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50 mg Carprofen.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Chewable tablets.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation, for example in
degenerative joint disease, in the dog.
Rimadyl Palatable Tablets can also be used in the management of
post-operative pain.
4.3 CONTRAINDICATIONS
Do not exceed the stated dose.
The elimination time of NSAIDs, including carprofen, in the cat is
longer than in the dog and the therapeutic index is
narrower. In the absence of specific data the use of Rimadyl Palatable
Tablets in the cat is contra-indicated.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a possibility of gastro-intestinal ulceration or
bleeding, or where there is evidence of blood dyscrasia or
hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of each
other. Some NSAIDs may be highly bound to plasma
proteins and compete with other highly bound drugs, which can lead to
toxic effects.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional risk. If such a use cannot be avoided, such dogs
may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided. NSAIDs can cause inhibition of phagocytosis and
hence in the treatment of inflammatory conditions associated with
bacterial infection, appropriate concurrent antimicrobial
therapy s